April 1, 2025: MDL Against Ozempic and Other GLP-1s Top 1,600 in April As of April 1, 2025, there are 1,685 active lawsuits pending against Novo Nordisk and other pharmaceutical companies that sold GLP-1 drugs like Ozempic
However, these effects are usually manageable with the right strategies, and they typically improve significantly after the first few weeks at each new dose level
Similarly, the profound benefits of L-carnitine in reducing metabolic strain and improving energy output have been exceptionally well-documented
Those with active malignancies or cancer history should still discuss peptide use with their healthcare providers
formulary tier: Who determines whether a patient receives oral or injectable GLP-1s
Liver health is a primary concern